TrueBinding Raises $100 Million To Develop Treatment For Alzheimer’s Disease

TrueBinding, Inc. raised investments of $100 million, according to a filing with the Securities Exchange Commission, to further its research on a treatment for Alzheimer’s disease. The company has not disclosed details.

The company was founded in 2016. In 2021, the U.S., Food and Drug Administration granted TrueBinding Investigational New Drug clearance for its Alzheimer’s disease treatment. A Phase 2 clinical trial is in process and is expected to conclude in October 2022.

TrueBinding Inc. is a clinical stage biotherapeutic company creating molecules for applications in neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, ALS . . .